Ellington Management Group LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, Holdings Channel reports. The fund purchased 16,500 shares of the medical equipment provider’s stock, valued at approximately $705,000.
Other hedge funds also recently made changes to their positions in the company. Grove Bank & Trust boosted its stake in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 1,535 shares in the last quarter. NuWave Investment Management LLC acquired a new stake in Hologic in the 4th quarter valued at $199,000. Advisor Partners LLC acquired a new stake in Hologic in the 4th quarter valued at $209,000. Fiduciary Trust Co. acquired a new stake in Hologic in the 4th quarter valued at $208,000. Finally, MPS Loria Financial Planners LLC acquired a new stake in Hologic in the 4th quarter valued at $214,000. 97.59% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently commented on HOLX. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Evercore ISI began coverage on Hologic in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 price target on the stock. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target on the stock in a research note on Monday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Friday, February 9th. Finally, Stifel Nicolaus lowered Hologic from a “buy” rating to a “hold” rating and decreased their price target for the company from $45.00 to $42.00 in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $48.00.
Hologic, Inc. (HOLX) opened at $38.93 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98. The company has a market capitalization of $10,942.26, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 1.78 and a beta of 0.84. Hologic, Inc. has a one year low of $35.33 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. The company had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 earnings per share. sell-side analysts expect that Hologic, Inc. will post 2.25 EPS for the current year.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.